Liquid Biopsy Reagent Industry Trends and Regulatory Compliance Insights

Regulatory Classification and Registration Pathways Are Becoming Increasingly Clear

In China, liquid biopsy reagents are generally regulated as in vitro diagnostic reagents, and the specific category must be determined comprehensively based on intended use, degree of risk, and detection targets. Some products intended for tumor companion diagnostics or auxiliary diagnosis of high-risk diseases may be regulated as Class III medical devices, requiring systematic analytical performance evaluation, stability studies, and clinical evaluation. Companies should communicate with regulators early in R&D to clarify product positioning and the registration pathway, avoiding increased change costs later due to improperly designed intended use.

In recent years, industry standards and technical guidance principles related to liquid biopsy have gradually improved, covering processes such as sample collection, nucleic acid extraction, library preparation and sequencing, and bioinformatics analysis. Manufacturers should monitor standard updates and translate general requirements into internal design inputs and release inspection items. Common practices include establishing product technical requirements, formulating quality standards for critical raw materials, and conducting regular supplier audits.

Supply Chain Stability and Critical Raw Material Management

Liquid biopsy reagents typically involve critical raw materials such as enzymes, antibodies, magnetic beads, adapters, primers and probes, and preservation solutions. The thermal stability, inhibitor resistance, and fidelity of enzymes directly affect reagent performance; the specificity and lot-to-lot consistency of antibodies are particularly important for immunocapture-based products. Companies should establish raw material incoming inspection, batch retention sampling, and change evaluation mechanisms to avoid product quality instability caused by fluctuations from a single supplier.

In supply chain management, multi-source evaluation may be conducted for critical materials, but when changing suppliers, sufficient verification must be carried out, including small-scale trials, pilot-scale trials, and stability observation. For components containing biologically active ingredients, storage temperature, shelf life, and transportation conditions should be clearly defined, and temperature-controlled recording devices should be used when necessary.

Trends Toward Automation and Data Compliance

The application of automated nucleic acid extraction, automated library preparation, and liquid handling workstations helps improve lot-to-lot consistency and testing throughput of liquid biopsy reagents. When designing kits, consideration may be given to compatibility with common automated equipment to reduce manual pipetting steps. Closed or semi-closed systems can reduce cross-contamination and operational errors, but consumable compatibility and maintenance costs need attention.

In terms of data compliance, bioinformatics analysis software, mutation annotation workflows, and reporting systems accompanying liquid biopsy, if regulated as medical device software, should meet corresponding cybersecurity, version control, and data traceability requirements. Companies should retain raw sequencing data, analysis parameters, and quality control records to ensure traceability of results. In promotion, absolute efficacy claims or exaggerated clinical significance must not be used, and the product's intended use, sample type, and performance boundaries should be described objectively.

Overall, the liquid biopsy reagent industry is moving from single markers toward multi-omics, automation, and standardization. While focusing on technological innovation, companies should simultaneously strengthen their quality systems and post-market surveillance to support long-term compliance and clinical application of their products.